Universal Scientific Industrial (Shanghai) (601231) Q1 2025 earnings summary

Executive summary

• Q1 2025 revenue reached RMB 13.65 billion, up 1.16% year-over-year, with net profit attributable to shareholders at RMB 335 million, a marginal increase of 0.08% year-over-year.

• Net profit after deducting non-recurring gains and losses was RMB 280 million, down 2.34% year-over-year.

• Net cash flows from operating activities decreased by 22.33% year-over-year to RMB 890 million.

Financial highlights

• Basic and diluted EPS remained at RMB 0.15, unchanged year-over-year.

• Weighted average return on equity was 1.85%, down 0.11 percentage points from the previous year.

• Total assets stood at RMB 39.34 billion as of March 31, 2025, down 1.65% from December 31, 2024.

• Owners' equity attributable to shareholders increased by 2.15% to RMB 18.32 billion.

Outlook and guidance

• Q2 2025 operating revenue is expected to decrease by approximately 10% year-over-year, with operating profit margin projected to decline by about 1 percentage point.

• Forward-looking statements are subject to uncertainties including global pandemic trends, trade conditions, EMS industry health, and order fulfillment.